Charles River Laboratories International, Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Strategic Review: Board supports strengthening scientific portfolio, divesting underperforming assets, maximizing financial performance, and disciplined capital deployment. Ongoing review of value creation options.
• Quarterly Results: Revenue in Q3 2025 was $1 billion, down 0.5% year-over-year. Organic revenue declined 1.6%. Operating margin was 19.7%, down 20 basis points. EPS was $2.43, down 6.2% year-over-year but above prior outlook.
• Cost Savings: Already implemented $225 million in annualized cost savings, with an additional $70 million expected in 2026 from procurement synergies, global business services, etc.
• NAMs: Focus on developing NAMs capabilities across segments, with support from a Scientific Advisory Board led by former FDA official. Examples include next-generation sequencing in biologics testing and animal-free endotoxin testing.

Segment Performance

• DSA Segment: Revenue in Q3 2025 was $600.7 million, a 3.1% organic year-over-year decrease. Organic revenue for the year is expected to decline 2.5%-3.5%. Operating margin in Q3 was 25.4%, down 200 basis points year-over-year.
• RMS Segment: Revenue was $213.5 million, a 6.5% organic increase year-over-year. Full-year organic revenue is expected to be flat to slightly positive. Operating margin increased to 25% in Q3.
• Manufacturing Segment: Revenue was $190.7 million, a 5.1% organic decrease year-over-year. Full-year organic revenue is expected to be flat to slightly negative. Operating margin in Q3 was 26.7%, down 200 basis points year-over-year.

Guidance

• Revenue: 2025 organic revenue expected to be in the range of 1.5%-2.5% decrease, narrowing from prior ranges.
• EPS: Non-GAAP EPS expected to be $10.10-$10.30, upper end of prior range.
• Margin: Operating margin flat to 30 basis point decline, unchanged from prior outlook.
• Free Cash Flow: Expected to be $470 million-$500 million, higher than prior outlook.

Risks

• Market Uncertainty: Continued uncertainty in biotech funding and end markets could impact revenue and margins.
• Divestiture Risks: Delays or issues in divesting underperforming assets could affect expected accretion and strategic goals.
• Tax Impact: Changes in tax legislation, such as the One Big Beautiful Bill Act, could impact the effective tax rate.

Question and Answer

• Q: Patrick Donnelly with Citi asks about book-to-bill and biotech market loosening.

A: Jim Foster discusses proposals up, cancellation levels down, and improved biotech funding.

• Q: David Windley with Jefferies asks about study start timing and divestitures.

A: Jim Foster talks about ability to start studies quickly and divestiture focus on ~7% of revenue.

• Q: Elizabeth Anderson with Evercore ISI asks about NAMs behavior and cost savings.

A: Jim Foster discusses NAMs adoption and Michael Knell details $70 million cost savings initiatives.

• Q: Eric Coldwell with Baird asks about DSA growth in 2026 and BIOSECURE Act.

A: Jim Foster is guardedly optimistic on 2026 DSA growth and notes no impact from BIOSECURE Act.

• Q: Justin Bowers with Deutsche Bank asks about DSA proposals and asset divestitures.

A: Jim Foster talks about proposal growth and divestiture progress.

• Q: Casey Woodring with JPMorgan asks about DSA margins and book-to-bill.

A: Michael Knell discusses NHP sourcing costs and Todd Spencer mentions monitoring trends.

• Q: Michael Ryskin with Bank of America asks about strategic review progress.

A: Jim Foster states strategic review first phase complete, moving to implementation.

• Q: Ann Hynes with Mizuho Securities asks about DSA backlog and capacity.

A: Jim Foster talks about capacity utilization and backlog lags.

• Q: Max Smock with William Blair asks about M&A impact and licensing.

A: Jim Foster says M&A and licensing are neutral to opportunities.

• Q: Luke Sergott with Barclays asks about DSA staffing and balance sheet.

A: Jim Foster discusses staffing needs and comfortable leverage levels.

• Q: Rob Cottrell with Cleveland Research asks about spot pricing and win rate.

A: Jim Foster talks about strategic pricing and no disclosure on win rate.